Bank of Nova Scotia
UTHR icon

Bank of Nova Scotia’s United Therapeutics UTHR Stock Holding History

Bank of Nova Scotia’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
2,315
-415
-15% -$234K ﹤0.01% 853
2026
Q1 		$1.62M Sell
2,730
-3,114
-53% -$1.55M ﹤0.01% 778
2025
Q4 		$2.85M Buy
5,844
+3,548
+155% +$1.65M ﹤0.01% 730
2025
Q3 		$963K Buy
2,296
+668
+41% +$225K ﹤0.01% 805
2025
Q2 		$468K Buy
1,628
+105
+7% +$31.4K ﹤0.01% 865
2025
Q1 		$469K Sell
1,523
-194
-11% -$66.5K ﹤0.01% 821
2024
Q4 		$606K Sell
1,717
-1,420
-45% -$522K ﹤0.01% 833
2024
Q3 		$1.12M Buy
3,137
+779
+33% +$263K ﹤0.01% 747
2024
Q2 		$751K Sell
2,358
-69,280
-97% -$18.3M ﹤0.01% 806
2024
Q1 		$16.5M Buy
71,638
+46,759
+188% +$10.6M 0.03% 303
2023
Q4 		$5.47M Buy
24,879
+21,822
+714% +$5.03M 0.01% 502
2023
Q3 		$690K Sell
3,057
-1,052
-26% -$242K ﹤0.01% 762
2023
Q2 		$907K Sell
4,109
-225
-5% -$49.8K ﹤0.01% 690
2023
Q1 		$971K Buy
+4,334
New +$1.07M ﹤0.01% 708
2022
Q2 		– Sell
-115,371
Closed -$20.7M – 1270
2022
Q1 		$20.7M Buy
115,371
+110,452
+2,245% +$21M 0.04% 327
2021
Q4 		$1.06M Sell
4,919
-172,277
-97% -$33.8M ﹤0.01% 982
2021
Q3 		$32.7M Buy
177,196
+174,351
+6,128% +$34.3M 0.06% 276
2021
Q2 		$510K Sell
2,845
-100
-3% -$19K ﹤0.01% 974
2021
Q1 		$493K Sell
2,945
-1,054
-26% -$176K ﹤0.01% 936
2020
Q4 		$607K Sell
3,999
-1,269
-24% -$167K ﹤0.01% 850
2020
Q3 		$532K Buy
5,268
+1,177
+29% +$129K ﹤0.01% 864
2020
Q2 		$495K Buy
+4,091
New +$460K ﹤0.01% 749
2019
Q3 		– Sell
-31,577
Closed -$2.46M – 955
2019
Q2 		$2.46M Buy
31,577
+10,577
+50% +$989K 0.01% 563
2019
Q1 		$2.46M Buy
+21,000
New +$2.45M 0.01% 583

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Bank of Nova Scotia's UTHR Position: Q2 2026 in Review

Bank of Nova Scotia reduced its United Therapeutics (UTHR) stake by 15% in Q2 2026, selling an estimated $234K and leaving 2,315 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Bank of Nova Scotia first reported a position in UTHR in Q1 2019 and has held it in 24 quarters since. The position peaked at $32.7M in Q3 2021. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Bank of Nova Scotia held 2,315 shares of United Therapeutics worth $1.25M as of Q2 2026.
  • Bank of Nova Scotia sold 415 United Therapeutics shares in Q2 2026, an estimated $234K.
  • United Therapeutics made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #853 holding.
  • Bank of Nova Scotia first reported a position in United Therapeutics in Q1 2019 and has held it in 24 quarters since.
  • Bank of Nova Scotia's United Therapeutics position peaked at $32.7M in Q3 2021.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.